<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">AID</journal-id><journal-title-group><journal-title>Advances in Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2164-2648</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/aid.2022.123033</article-id><article-id pub-id-type="publisher-id">AID-119634</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Hepatitis B in Senegalese Blood Donors: Low Prevalence after Five Blood Donations?
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Papa</surname><given-names>Silman Diawara</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mamadou</surname><given-names>Wague Gueye</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sokhna</surname><given-names>M. Daffe</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mor</surname><given-names>Ngom</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Maguette</surname><given-names>Ndoye</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nata</surname><given-names>Dieng</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ibrahima</surname><given-names>Diallo</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bécaye</surname><given-names>Fall</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Macoura</surname><given-names>Gadji</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Moustapha</surname><given-names>Diop</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Pape</surname><given-names>Samba Ba</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yankhoba</surname><given-names>Diop</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff5"><addr-line>Infectious Diseases Department, Dakar Principal Hospital, Dakar, Senegal</addr-line></aff><aff id="aff3"><addr-line>Hepato-Gastro-Enterology Department, Dakar Principal Hospital, Dakar, Senegal</addr-line></aff><aff id="aff4"><addr-line>Department of Biological Hematology &amp;amp; Oncology—Hematology (HBOH), National Blood Transfusion Center (CNTS)/FMPOS-UCAD, Dakar, Senegal</addr-line></aff><aff id="aff2"><addr-line>Hematology Department, Dakar Principal Hospital, Dakar, Senegal</addr-line></aff><aff id="aff1"><addr-line>Federation of Laboratories, Principal Hospital of Dakar, Dakar, Senegal</addr-line></aff><pub-date pub-type="epub"><day>22</day><month>07</month><year>2022</year></pub-date><volume>12</volume><issue>03</issue><fpage>422</fpage><lpage>432</lpage><history><date date-type="received"><day>28,</day>	<month>July</month>	<year>2022</year></date><date date-type="rev-recd"><day>30,</day>	<month>August</month>	<year>2022</year>	</date><date date-type="accepted"><day>2,</day>	<month>September</month>	<year>2022</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background: Over the past two decades, blood transfusion safety has made significant advances in the fight against infectious diseases. However, hepatitis B is still a problem in blood banks due to its high endemicity in Senegal. In this context, we proposed to first determine the prevalence of HBs antigen (HBsAg) in regular and new blood donors. Second, to determine the influence of the number of blood donations on the prevalence of hepatitis B. 
  Materials and Method: We conducted a retrospective transversal study using data from all blood donations received at the Principal Hospital of Dakar Blood bank from July 2007 to December 31, 2021. Hepatitis B testing was carried out with Automaton E411 (Roche Diagnostics). For all donors, information on age, sex, hepatitis B serology, and the number of donations was collected through the lab’s computer system. Data entry and statistical analysis were performed with Epi-info version 7. 
  Results: HBsAg carriers were identified in 4311 primary donors, corresponding to a prevalence of 12.39% (IC 95% = 12.04 - 12.74). The prevalence of the HBsAg antigen was higher in men (12.9%) than in women (6.85%). Men are twice as likely to be infected with HBV as women (OR = 2.00 (IC 95% = 1.85 - 2.17)). The highest prevalence (12.4%) was found in young adults (23 - 29) years old. After 10 donations, the prevalence of the HBs antigen was stable at around 1%. Individuals with a single blood donation and individuals with 2 to 5 blood donations are 9 and 7 times more likely to carry the HBs antigen than regular donors (more than 10 blood donations), respectively. 
  Conclusion: Our results demonstrate the endemic nature of hepatitis B in Senegal. On the other hand, the non-negligible prevalence of the virus in first-time donors reminds us of the need for continuous improvement in donor selection. These first-time donors, particularly young adults, are important indicators of transmission of the virus to the general population. This study also demonstrates the need to develop strategies to maintain the pool of regular donors, which represent significant barriers to the spread of hepatitis B.
 
</p></abstract><kwd-group><kwd>First-Time Donor</kwd><kwd> Regular Donor</kwd><kwd> Hepatitis B</kwd><kwd> Prevalence</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Over the past two decades, the safety of blood transfusions has made significant progress in the fight against infectious diseases and immunological risks. In Senegal, hepatitis B is the main risk, infecting 11% - 15% of adults. HBV infection is a major cause of liver disease and the most important risk factor for liver cancer. The WHO strongly recommends the collection of blood from regular, volunteer, and unpaid donors from low-risk populations [<xref ref-type="bibr" rid="scirp.119634-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.119634-ref2">2</xref>]. Several studies, including those of Zimbabwe’s Tonderai Mapako, have demonstrated that the probability of finding infection is lower in a regular donor than in a primary donor. However, regular donors do not cover the increasing need for blood in response to various medical and surgical emergencies. The single donor, voluntary or substitute, is a very common alternative in recruiting blood bank donors. This risk is also exacerbated by high endemic HBV infection, with 85% of the overall population having at least one HBV marker [<xref ref-type="bibr" rid="scirp.119634-ref3">3</xref>]. In Senegal, few studies have focused on the characterization of HB antigen carriers in both new and regular donors. This characterization, even if carried out, does not sufficiently highlight simple and accessible parameters such as age, gender, and the number of donations. These characteristics are fundamental elements that must be taken into account when combating the transmission of the hepatitis B virus. For all these reasons, we proposed to first study the prevalence of HBs antigen (HBsAg) among regular and new blood donors in the main hospital of Dakar. Second, to determine the influence of the number of blood donations on the prevalence of hepatitis B in blood donors. The prevalence of hepatitis B in these different blood donor groups helps assess the risk of transfusion infection and the extent of hepatitis B endemicity in the general population.</p></sec><sec id="s2"><title>2. Method</title><sec id="s2_1"><title>2.1. Study Area Description</title><p>The blood bank at the Principal Hospital of Dakar (HPD) is located in the Dakar Plateau district in Senegal. Principal Hospital of Dakar (HPD) is a public health facility with military status. It is a Level 3 hospital with 471 beds and an independent blood bank for patient care (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p></sec><sec id="s2_2"><title>2.2. Study Design</title><p>We conducted a retrospective transversal study using data from all blood donations received at the Principal Hospital of Dakar Blood bank from July 2007 to December 31, 2021. Donors fill out a form that includes information to assess the health risk of the donation to the donor and the prospective patient. People at high risk for infectious transmission (sexual activity, transfusions…) and vulnerable persons (pregnant women, breastfeeding, diabetics…) were not eligible for blood donation. One 450 mL blood bag and two 5 mL tubes were collected for serological testing in individuals who met the donation criteria. Excluded candidates were given a simple infection test. Hepatitis B testing was carried out with Automaton E411 (Roche Diagnostics). The tests were carried out using an immunological technique based on the principle of chemiluminescence of the collected human serums.</p></sec><sec id="s2_3"><title>2.3. Study Population</title><p>The study population consisted of two categories of donors depending on the donor site.</p><p>Collection in Principal Hospital of Dakar blood bank</p><p>‒ Donors who came to the blood bank voluntarily without payment to donate blood to someone they do not know.</p><p>‒ Donors who came to the blood bank for the benefit of a sick relative in the hospital or other medical institution</p><p>Collection outside Principal Hospital of Dakar blood bank</p><p>‒ Donors are recruited from external collections from military camps or charitable activities.</p></sec><sec id="s2_4"><title>2.4. Data Collection and Analysis</title><p>For all donors, information on age, sex, hepatitis B serology, and the number of donations was collected through the lab’s computer system. Data entry and statistical analysis were performed with Epi-info version 7. Results were reported as mean and standard deviation (SD) or median in an interquartile range for quantitative variables. Whereas for categorized variables, the number and percentage of subjects in each category were computed. Prevalence’s was given with a 95% confidence interval (IC 95%). Outcome variables were HBsAg (HBs antigen) positive or negative serostatus. Cross-tabulations were created from the outcome variables and the socio-demographic variables (age, gender, hepatitis B serology, number of donations). Chi-square or Fisher’s exact test was used as a statistical significance test to compare sociodemographic variables with HBs antigen seropositivity. A p-value &lt; 0.05 from two-tailed tests was considered significant in all tests. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to determine associations between sociodemographic variables and seropositive status for HBs antigen.</p></sec><sec id="s2_5"><title>2.5. Inclusion and Exclusion Criteria</title><sec id="s2_5_1"><title>2.5.1. Inclusion Criteria</title><p>All donors were recruited during the study period. After the validation of the questionnaire and the preliminary medical examination, a donor will be recruited. Donors must meet the following non-exhaustive eligibility criteria set out below.</p><p>‒ Age between 16 and 65 years.</p><p>‒ Haemoglobin—not less than 12.5 g/Dl.</p><p>‒ Pulse - normal with no irregularities.</p><p>‒ Blood Pressure—Normal.</p><p>‒ Temperature—Normal.</p><p>‒ Body weight—not less than 45 Kg.</p><p>‒ Past six months—not had a tattoo, ear or skin piercing or acupuncture, not received blood or blood products, no serious illness or major surgery, no contact with a person with hepatitis or yellow jaundice…</p><p>‒ Past three months—not donated blood or been treated for Malaria.</p><p>‒ Past one month—had any immunizations.</p><p>‒ Past 48 hours—taken any antibiotics or any other medications.</p><p>‒ Past 24 hours—taken alcoholic beverages.</p><p>‒ Past 72 hours—had dental work or taken Aspirin.</p><p>‒ Present—not suffering from cough, influenza or sore throat, common cold.</p><p>‒ Women should not be pregnant or breast feeding her child.</p><p>‒ Women donor should not donate during her menstrual cycles.</p><p>‒ Free from Diabetes, not suffering from chest pain, heart disease or high BP, cancer, blood clotting problem or blood disease, unexplained fever, weight loss, fatigue, night sweats etc.</p></sec><sec id="s2_5_2"><title>2.5.2. Exclusion Criteria</title><p>Donors whose medical records were not traceable were excluded from the study.</p></sec></sec><sec id="s2_6"><title>2.6. HBs Antigen Screening</title><p>Two 5 mL tubes were collected for serological testing from individuals who met the donation criteria. Excluded candidates were given a simple infection test. Hepatitis B testing was carried out with Automaton E411 (Roche Diagnostics). The tests were carried out using an immunological technique based on the principle of chemiluminescence of the collected human serums.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Blood Donor Population</title><p>A total of 45,939 blood donors were registered, of which 32,269 (70%) were male and 13,670 (30%) female, which corresponds to a gender ratio of 2.33. The youngest donor was 16 years old compared to 65 years for the oldest donor. The donors had a mean and median age of 32 and 29 years, respectively. The population is young, with 53% of donors under the age of 30. The majority of the population, 39,099 (85%), were at their first blood donation, followed by blood donation group 2 - 5, which made up 12% of the people. The remaining population of regular donors is less than 3% of donors. The characteristics of the study population are summarized in <xref ref-type="table" rid="table1">Table 1</xref>.</p></sec><sec id="s3_2"><title>3.2. First-Time Blood Donor Population and Hepatitis B Carriage</title><p>HBsAg carriers were identified in 4311 primary donors, corresponding to a prevalence of 12.39% (IC 95% = 12.04 - 12.74). The prevalence of the HBsAg antigen was higher in men (12.9%) than in women (6.85%). Men are twice as likely</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Characteristics of the study population</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Characteristic</th><th align="center" valign="middle" >1_donation, N = 39,099<sup>1</sup></th><th align="center" valign="middle" >2 - 5 donations, N = 5,523<sup>1</sup></th><th align="center" valign="middle" >5 - 10 donations, N = 645<sup>1</sup></th><th align="center" valign="middle" >10 - 20 donations, N = 396<sup>1</sup></th><th align="center" valign="middle" >20 - 30 donations, N = 170<sup>1</sup></th><th align="center" valign="middle" >Over_30_ donations, N = 106<sup>1</sup></th><th align="center" valign="middle" >p-value<sup>b</sup></th></tr></thead><tr><td align="center" valign="middle" >Age <sup>a</sup></td><td align="center" valign="middle" >28 (22, 38)</td><td align="center" valign="middle" >33 (25, 44)</td><td align="center" valign="middle" >44 (34, 53)</td><td align="center" valign="middle" >47 (38, 57)</td><td align="center" valign="middle" >50 (42, 57)</td><td align="center" valign="middle" >48 (43, 55)</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >age category</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >16 - 23</td><td align="center" valign="middle" >12,870 (33%)</td><td align="center" valign="middle" >1004 (18%)</td><td align="center" valign="middle" >17 (2.6%)</td><td align="center" valign="middle" >3 (0.8%)</td><td align="center" valign="middle" >0 (0%)</td><td align="center" valign="middle" >1 (0.9%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >23 - 29</td><td align="center" valign="middle" >9015 (23%)</td><td align="center" valign="middle" >1250 (23%)</td><td align="center" valign="middle" >70 (11%)</td><td align="center" valign="middle" >36 (9.1%)</td><td align="center" valign="middle" >3 (1.8%)</td><td align="center" valign="middle" >3 (2.8%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >29 - 39</td><td align="center" valign="middle" >8550 (22%)</td><td align="center" valign="middle" >1397 (25%)</td><td align="center" valign="middle" >165 (26%)</td><td align="center" valign="middle" >72 (18%)</td><td align="center" valign="middle" >31 (18%)</td><td align="center" valign="middle" >13 (12%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >39 - 65</td><td align="center" valign="middle" >8664 (22%)</td><td align="center" valign="middle" >1872 (34%)</td><td align="center" valign="middle" >393 (61%)</td><td align="center" valign="middle" >285 (72%)</td><td align="center" valign="middle" >136 (80%)</td><td align="center" valign="middle" >89 (84%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Gender</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >11,933 (31%)</td><td align="center" valign="middle" >1455 (26%)</td><td align="center" valign="middle" >177 (27%)</td><td align="center" valign="middle" >78 (20%)</td><td align="center" valign="middle" >18 (11%)</td><td align="center" valign="middle" >9 (8.5%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >27,166 (69%)</td><td align="center" valign="middle" >4068 (74%)</td><td align="center" valign="middle" >468 (73%)</td><td align="center" valign="middle" >318 (80%)</td><td align="center" valign="middle" >152 (89%)</td><td align="center" valign="middle" >97 (92%)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>a. 1 Median (IQR); n (%); b. 2 Kruskal-Wallis rank sum test; Pearson’s Chi-squared test.</p><p>to be infected with HBV as women (OR = 2.00 (IC 95% = 1.85 - 2.17)). The 39 to 65 age group has the lowest prevalence at 8.73%. The highest prevalence (12.4%) was found in young adults (23 - 29). Compared to the 39 - 65 age group, the risk is higher for 23 - 29 years old, 29 - 39 years old, and 16 - 23 years old with respective ratios of 1.49, 1, 40, and 1.30. The characteristics of HBV carriers are summarized in <xref ref-type="table" rid="table2">Table 2</xref>.</p></sec><sec id="s3_3"><title>3.3. Impact of Blood Donation Number on the Prevalence</title><p>The presence of HBs antigen decreased based on the number of blood donations performed with 11.0%, 8.82% of the HBs seroprevalence for the 1-donation and 2 - 5-donation groups, respectively. After 10 donations, the prevalence of the HBs antigen was stable at around 1%. Individuals with a single blood donation and individuals with 2 to 5 blood donations are 9 and 7 times more likely, respectively, to be carriers of the HBs antigen than regular donors (more than 10 blood donations).</p></sec></sec><sec id="s4"><title>4. Discussion</title><sec id="s4_1"><title>4.1. Hepatitis B Prevalence</title><p>The results of our study confirm the endemic nature of HBV infection in Senegal, consistent with previous studies [<xref ref-type="bibr" rid="scirp.119634-ref4">4</xref>] since 12.39% (IC 95% = 12.04 - 12.74) of donors were positive for HBs antigen. Our results are similar to those of Macoura et al., who found an HBs antigen prevalence of 12.67% in 163,787 donors</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Characteristics of first-time blood donor</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >[ALL] N = 39,099</th><th align="center" valign="middle" >Negative N = 34,788</th><th align="center" valign="middle" >Positive N = 4311</th><th align="center" valign="middle" >OR</th><th align="center" valign="middle" >p. ratio</th><th align="center" valign="middle" >p. overall</th></tr></thead><tr><td align="center" valign="middle" >Age, Mean (SD)</td><td align="center" valign="middle" >31.0 [30.8; 31.1]</td><td align="center" valign="middle" >31.1 [31.0; 31.2]</td><td align="center" valign="middle" >30.0 [29.7; 30.3]</td><td align="center" valign="middle" >0.99 [0.99; 0.99]</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Age category, N (%):</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >16 - 23</td><td align="center" valign="middle" >32.9% [100.0%; 100%]</td><td align="center" valign="middle" >88.9% [88.4%; 89.5%]</td><td align="center" valign="middle" >11.1% [10.5%; 11.6%]</td><td align="center" valign="middle" >1.30 [1.19; 1.43]</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >23 - 29</td><td align="center" valign="middle" >23.1% [100.0%; 100%]</td><td align="center" valign="middle" >87.6% [86.9%; 88.2%]</td><td align="center" valign="middle" >12.4% [11.8%; 13.1%]</td><td align="center" valign="middle" >1.49 [1.35; 1.64]</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >29 - 39</td><td align="center" valign="middle" >21.9% [100.0%; 100%]</td><td align="center" valign="middle" >88.2% [87.5%; 88.9%]</td><td align="center" valign="middle" >11.8% [11.1%; 12.5%]</td><td align="center" valign="middle" >1.40 [1.27; 1.55]</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >39 - 65</td><td align="center" valign="middle" >22.2% [100.0%; 100%]</td><td align="center" valign="middle" >91.3% [90.7%; 91.9%]</td><td align="center" valign="middle" >8.73% [8.14%; 9.34%]</td><td align="center" valign="middle" >Ref.</td><td align="center" valign="middle" >Ref.</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Gender, N (%):</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >Female</td><td align="center" valign="middle" >30.5% [100.0%; 100%]</td><td align="center" valign="middle" >93.1% [92.7%; 93.6%]</td><td align="center" valign="middle" >6.85% [6.41%; 7.32%]</td><td align="center" valign="middle" >Ref.</td><td align="center" valign="middle" >Ref.</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Male</td><td align="center" valign="middle" >69.5% [100.0%; 100%]</td><td align="center" valign="middle" >87.1% [86.7%; 87.5%]</td><td align="center" valign="middle" >12.9% [12.5%; 13.3%]</td><td align="center" valign="middle" >2.00 [1.85; 2.17]</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>in a study evaluating test performance at the National Blood Transfusion Center in Dakar [<xref ref-type="bibr" rid="scirp.119634-ref3">3</xref>]. This prevalence is consistent with the results of Apata et al., who reported a slightly increased prevalence of approximately 11% (10.50% in 2004 and 10.51% in 2010) among Senegalese blood donors in the Global Database for Blood Safety [<xref ref-type="bibr" rid="scirp.119634-ref5">5</xref>]. A similar prevalence of 11.7% was reported in 2003 among 3001 blood donors recruited in 7 blood centers in Senegal [<xref ref-type="bibr" rid="scirp.119634-ref6">6</xref>]. In the Ziguinchor blood bank, a prevalence of 10.5% was found in a population of 2613 blood donors [<xref ref-type="bibr" rid="scirp.119634-ref7">7</xref>]. Overall, the seroprevalence of hepatitis B antigen in Senegalese blood donors varies slightly around 11% across studies. Results vary greatly in neighboring countries with prevalences often higher than 10%. The highest rates are found in Mauritania (20.3%) [<xref ref-type="bibr" rid="scirp.119634-ref8">8</xref>], Guinea Conakry (16.4%) [<xref ref-type="bibr" rid="scirp.119634-ref9">9</xref>], Niger (15.4%) [<xref ref-type="bibr" rid="scirp.119634-ref10">10</xref>], Mali. (13.9%) [<xref ref-type="bibr" rid="scirp.119634-ref11">11</xref>], Burkina Faso (13.4%) [<xref ref-type="bibr" rid="scirp.119634-ref12">12</xref>]. intermediate values similar to ours are found in Cameroon (12.6%) [<xref ref-type="bibr" rid="scirp.119634-ref13">13</xref>], Ivory Coast (12.5%) [<xref ref-type="bibr" rid="scirp.119634-ref14">14</xref>], DR Congo (9.2%) [<xref ref-type="bibr" rid="scirp.119634-ref14">14</xref>]. Factors that may explain this variability include the predominant mode of virus transmission (vertical or horizontal) and the sociodemographic characteristics of the blood donor population. The mode of transmission also explains the low prevalence in North Africa and industrialized countries, where hepatitis has generally occurred in adulthood. In these northern countries, the prevalence is generally below 5%; 1.34% in Morocco [<xref ref-type="bibr" rid="scirp.119634-ref15">15</xref>], 4.3% in Egypt [<xref ref-type="bibr" rid="scirp.119634-ref16">16</xref>], 0.0069% in Italy [<xref ref-type="bibr" rid="scirp.119634-ref17">17</xref>] and 0.007% in Canada. Interestingly, we found that individuals aged 23 - 29 years had a higher HBs antigen prevalence (12.4%) than other groups. Almost a quarter of our donor population (23%) consists of people in the 23 - 29 age group. They are typically young adults in their prime and are more likely to donate blood. The similar age group of 18 - 28 years had the highest prevalence rates in a study of blood donors in Ziguinchor, a region of Senegal [<xref ref-type="bibr" rid="scirp.119634-ref7">7</xref>]. This group is considered by several authors to be most at risk for HBs antigen seropositivity due to the addition of sexual risk factors [<xref ref-type="bibr" rid="scirp.119634-ref18">18</xref>]. Several studies have focused on sexual risk, particularly in Ethiopia, where 3/4 of the Jimma Blood Bank volunteer donors who tested positive were under the age of 40. In the same study, the rate of test positivity was slightly higher among the unmarried than among the married study participants [<xref ref-type="bibr" rid="scirp.119634-ref19">19</xref>]. In China, the prevalence pattern for Hepatitis B is different, the highest prevalence was found in the youngest age group (1825 years) in the Zhen Wang study [<xref ref-type="bibr" rid="scirp.119634-ref20">20</xref>]. Similar results have been—in young adults in China, Ghana, and Gabon, where the prevalence of HBsAg in both sexes tends to increase with age in both sexes, peaking around age 40. In our study, the prevalence of the HBs antigen subsequently drops to 7.46% in 39 to 65 years old. The general decrease in the prevalence of HBsAg beyond 40 years of age has already been reported [<xref ref-type="bibr" rid="scirp.119634-ref21">21</xref>]. For some authors, this decrease would be related to the elimination of the virus in most elderly subjects. The other interesting fact of our study is the low prevalence rate observed in female donors with a prevalence of 6.60% versus 12.1% in males. This higher prevalence in male donors has been reported by several authors [<xref ref-type="bibr" rid="scirp.119634-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.119634-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.119634-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.119634-ref24">24</xref>] including Getinet Ayano et al. in a meta-analysis [<xref ref-type="bibr" rid="scirp.119634-ref25">25</xref>]. The mechanism of gender disparity in the onset and progression of hepatitis virus infection is believed to be partly related to the more synergistic effect of female sex hormones on the immune response. Female donors appear to be much safer than males against HBV and should be encouraged to donate.</p></sec><sec id="s4_2"><title>4.2. Impact of Blood Donation Number</title><p>Our results also show that the prevalence decreases with the number of blood donations. The prevalence of HBV is 11% and 8.8% in people with 1 donation and 2 - 5 donations, respectively. The prevalence after 5 donations is in the 1% range (see <xref ref-type="table" rid="table3">Table 3</xref>), indicating the rarity of hepatitis B occurrence in regular blood donors. This phenomenon was observed in several countries: China [<xref ref-type="bibr" rid="scirp.119634-ref20">20</xref>], and Brazil [<xref ref-type="bibr" rid="scirp.119634-ref26">26</xref>], where the HBV prevalence in first-time donors was significantly higher than in repeat donors. The HBsAg prevalence in repeat donors was low and stable, reflecting the rare case of new infections occurring between blood donations. Individuals with a single blood donation and those with 2 to 5 blood donations are 9 and 7 times more likely to be carriers of the HBs antigen than normal donors (more than 10 blood donations), respectively. The fact that regular donors have lower HBs antigen levels can be explained by several factors. The first reason is that the majority of donors who donated more than 5 (61%) are in the 39 to 65 age group. It is common knowledge that most donors at this age are already infected with the virus and have recovered from hepatitis B disease. The second reason is that donors over the age of 40 are more mature and less likely to engage in risk-take behaviors that can lead to sexual infections. The last point is that people who donated more than five times have already been screened multiple times. Repeat blood donors are therefore less at risk than new donors who never go through the screening process Similar results confirm that first-time donors have higher hepatitis B infection rates compared to regular and repeat blood donors [<xref ref-type="bibr" rid="scirp.119634-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.119634-ref28">28</xref>].</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> HBs antigen prevalence and blood donation</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >HBs Ag negative N = 41,124</th><th align="center" valign="middle" >HBsAg Positive N = 4815</th><th align="center" valign="middle" >OR</th><th align="center" valign="middle" >p. ratio</th><th align="center" valign="middle" >p-value<sup>2</sup></th><th align="center" valign="middle" >N</th></tr></thead><tr><td align="center" valign="middle" >Donation group, N (%):</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" >45,939</td></tr><tr><td align="center" valign="middle" >1_donation</td><td align="center" valign="middle" >34,788 (89.0%)</td><td align="center" valign="middle" >4311 (11.0%)</td><td align="center" valign="middle" >8.97 [4.94; 18.8]</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >2 - 5 donations</td><td align="center" valign="middle" >5036 (91.2%)</td><td align="center" valign="middle" >487 (8.82%)</td><td align="center" valign="middle" >7.00 [3.83; 14.8]</td><td align="center" valign="middle" >&lt;0.001</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >5 - 10 donations</td><td align="center" valign="middle" >637 (98.8%)</td><td align="center" valign="middle" >8 (1.24%)</td><td align="center" valign="middle" >0.93 [0.34; 2.47]</td><td align="center" valign="middle" >0.879</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >10_donations</td><td align="center" valign="middle" >663 (98.7%)</td><td align="center" valign="middle" >9 (1.34%)</td><td align="center" valign="middle" >Ref.</td><td align="center" valign="middle" >Ref.</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap></sec></sec><sec id="s5"><title>5. Conclusion</title><p>Our results demonstrate the endemic nature of hepatitis B in Senegal. On the other hand, the non-negligible prevalence of the virus in first-time donors reminds us of the need for continuous improvement in donor selection. These first-time donors, particularly young adults, are important indicators of transmission of the virus to the general population. This study also demonstrates the need to develop strategies to maintain the pool of regular donors, which represent significant barriers to the spread of hepatitis B.</p></sec><sec id="s6"><title>Acknowledgements</title><p>We thank the blood bank donors of Dakar Principal Hospital and all Principal doctors, technicians and nurses for their support in making the study a success.</p></sec><sec id="s7"><title>Authors’ Contributions</title><p>All authors were involved in data collection and the preparation of the final manuscript</p></sec><sec id="s8"><title>Conflicts of Interest</title><p>The authors declare that they have no competing interests.</p></sec><sec id="s9"><title>Cite this paper</title><p>Diawara, P.S., Gueye, M.W., Daffe, S.M., Ngom, M., Ndoye, M., Dieng, N., Diallo, I., Fall, B., Gadji, M., Diop, M., Ba, P.S. and Diop, Y. (2022) Hepatitis B in Senegalese Blood Donors: Low Prevalence after Five Blood Donations? Advances in Infectious Diseases, 12, 422-432. https://doi.org/10.4236/aid.2022.123033</p></sec><sec id="s10"><title>List of Abbreviations</title><p>HBsAg: Hepatitis B surface Antigen; HPD: Principal Hospital of Dakar; WHO: World Health Organization</p></sec></body><back><ref-list><title>References</title><ref id="scirp.119634-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ankouane, F., Noah Noah, D., Atangana, M.M., et al. (2016) Seroprevalence of Hepatitis B and C Viruses, HIV-1/2 and Syphilis among Blood Donors in the Yaoundé Central Hospital in the Centre Region of Cameroon. Transfusion Clinique et Biologique, 23, 72-77.</mixed-citation></ref><ref id="scirp.119634-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kabinda, J.M., Miyanga, S.A., Misingi, P. and Ramazani, S.Y. (2014) Hepatitis B and C among Volunteer Non-Remunerated Blood Donors in Eastern Democratic Republic of Congo. Transfusion Clinique Et Biologique: Journal De La Societe Francaise De Transfusion Sanguine, 21, 111-115. https://doi.org/10.1016/j.tracli.2014.04.001</mixed-citation></ref><ref id="scirp.119634-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Sbai, A., Baha, W., Ougabrai, H., Allalia, T., Dersi, N., Lazaar, F., et al. (2011) Hepatitis B Prevalence and Risk Factors in Morocco. Pathologie-biologie, 60, e65-e69. https://doi.org/10.1016/j.patbio.2011.06.001</mixed-citation></ref><ref id="scirp.119634-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Omran, D. and Abdalla, M. (2014) Safety of Blood Transfusion: An Egyptian Study. Journal of Infectious Diseases and Therapy, 2, Article ID: 1000124. https://doi.org/10.4172/2332-0877.1000124</mixed-citation></ref><ref id="scirp.119634-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Gonzalez, M., Règine, V., Piccinini, V., Vulcano, F., Giampaolo, A. and Hassan, H.J. (2005) Residual Risk of Transfusion-Transmitted Human Immunodeficiency Virus, Hepatitis C Virus, and Hepatitis B Virus Infections in Italy. Transfusion, 45, 1670-1675. https://doi.org/10.1111/j.1537-2995.2005.00576.x</mixed-citation></ref><ref id="scirp.119634-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Allain, J.-P., Owusu-Ofori, S., Ye, X., Bisseye, C., Chaar, M.E. and Li, C. (2022) Hepatitis B Virus Chronic Infection in Blood Donors from Asian and African High or Medium Prevalence Areas: Comparison According to Sex. Viruses, 14, 673. https://doi.org/10.3390/v14040673</mixed-citation></ref><ref id="scirp.119634-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Yigezu, H., Temam, J., Bajiro, M., Tesfaye Jule, L., Nagaprasad, N., Roy, A., et al. (2022) Factors Associated with the Prevalence of Hepatitis B among Volunteer Blood Donors at Jimma Blood Bank, South Ethiopia. Canadian Journal of Gastroenterology and Hepatology, 2022, e7458747. https://doi.org/10.1155/2022/7458747</mixed-citation></ref><ref id="scirp.119634-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Z., Zeng, J., Li, T., Zheng, X., Xu, X., Ye, X., et al. (2016) Prevalence of Hepatitis B Surface Antigen (HBsAg) in a Blood Donor Population Born Prior to and After Implementation of Universal HBV Vaccination in Shenzhen, China. BMC Infectious Diseases, 16, Article No. 498. https://doi.org/10.1186/s12879-016-1834-2</mixed-citation></ref><ref id="scirp.119634-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ott, J.J., Stevens, G.A., Groeger, J. and Wiersma, S.T. (2012) Global Epidemiology of Hepatitis B Virus Infection: New Estimates of Age-Specific HBsAg Seroprevalence and Endemicity. Vaccine, 30, 2212-2219. https://doi.org/10.1016/j.vaccine.2011.12.116</mixed-citation></ref><ref id="scirp.119634-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">O’Brien, S.F., Xi, G., Fan, W., Yi, Q.-L., Fearon, M.A., Scalia, V., et al. (2008) Epidemiology of Hepatitis B in Canadian Blood Donors. Transfusion, 48, 2323-2330. https://doi.org/10.1111/j.1537-2995.2008.01845.x</mixed-citation></ref><ref id="scirp.119634-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Shepard, C.W., Simard, E.P., Finelli, L., Fiore, A.E. and Bell, B.P. (2006) Hepatitis B Virus Infection: Epidemiology and Vaccination. Epidemiologic Reviews, 28, 112-125. https://doi.org/10.1093/epirev/mxj009</mixed-citation></ref><ref id="scirp.119634-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">B&amp;#248;rresen, M.L., et al. (2015) Hepatitis B Prevalence and Incidence in Greenland: A Population-Based Cohort Study. American Journal of Epidemiology, 181, 422-430.</mixed-citation></ref><ref id="scirp.119634-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ayano, G., Tulu, M., Haile, K., Assefa, D., Habtamu, Y., Araya, G., et al. (2018) A Systematic Review and Meta-Analysis of Gender Difference in Epidemiology of HIV, Hepatitis B, and Hepatitis C Infections in People with Severe Mental Illness. Annals of General Psychiatry, 17, Article No. 16. https://doi.org/10.1186/s12991-018-0186-2</mixed-citation></ref><ref id="scirp.119634-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Silveira, L., Schiavon, L.L., Silva, K.P., Lopes, T.B., Zaccaron, M.R. and Nar-ciso-Schiavon, J.L. (2011) Clinical and Epidemiological Profile of Blood Donors with Positive Serology for Viral Hepatitis in Southern Brazil. Revista Da Sociedade Brasileira de Medicina Tropical, Sociedade Brasileira de Medicina Tropical, 44, 269-273. https://doi.org/10.1590/S0037-86822011005000028</mixed-citation></ref><ref id="scirp.119634-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Saba, N., Nasir, J.A., Waheed, U., Aslam, S., Mohammad, I., Wazeer, A., et al. (2021) Sero-Prevalence of Transfusion-Transmitted Infections among Voluntary and Replacement Blood Donors at the Peshawar Regional Blood Centre, Khyber Pakhtunkhwa, Pakistan. Journal of Laboratory Physicians, 13, 162-168. https://doi.org/10.1055/s-0041-1729485</mixed-citation></ref><ref id="scirp.119634-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Masaeli, Z., Jaberi, M. and Magsudlu, M. (2006) A Comparison of Seroprevalence of Blood-Borne Infections among Regular, Sporadic, and First-Time Blood Donors in Isfahan. Scientific Journal of Iran Blood Transfus Organ, 2, 301-307.</mixed-citation></ref><ref id="scirp.119634-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Sawadogo, A., Ouédraogo, A.S., Poda, A., Dahourou, H., Pivert, A., Mansour, W., et al. (2016) Seroprevalence of Hepatitis D Virus Infection in a Population of blood donors with Antigene HBs at the Bobo-Dioulasso Regional Blood Transfusion Centre, Burkina Faso. Journal Africain d’Hépato-Gastroentérologie, 10, 31-33. https://doi.org/10.1007/s12157-015-0646-4</mixed-citation></ref><ref id="scirp.119634-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Diarra, A., et al. (2009) HIV, HCV, HBV and Syphilis Rate of Positive Donations among Blood Donations in Mali: Lower Rates among Volunteer Blood Donors. Transfusion Clinique et Biologique, 16, 444-447.</mixed-citation></ref><ref id="scirp.119634-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Mayaki, Z., Dardenne, N., Kabo, R., Moutschen, M., Sondag, D., Albert, A., et al. (2013) Seroprevalence of Infectious Markers among Blood Donors in Niamey (Niger). Revue d’Epidemiologie Et De Sante Publique, 61, 233-240. https://doi.org/10.1016/j.respe.2012.12.018</mixed-citation></ref><ref id="scirp.119634-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Boumbaly, S., et al. (2022) Prevalence of Viral Hepatitis B Markers among Blood Donors in the Republic of Guinea. Voprosy Virusologii, 67, 59-68.</mixed-citation></ref><ref id="scirp.119634-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Lo, B.B., Meymouna, M., Boulahi, M.A., Tew, M., Sow, A., Ba, A., et al. (1999) Prevalence of Serum Markers of Hepatitis B and C Virus in Blood Donors of Nouakchott, Mauritania. Bulletin De La Societe De Pathologie Exotique (1990), 92, 83-84.</mixed-citation></ref><ref id="scirp.119634-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Sarr, H., Coly, M.N., Diop, A., Niang, A.A., Dieye, B., Diallo, F., et al. (2021) Seroprevalence of Markers of Infectious Agents (HIV, HBV, HCV and Syphilis) in Blood Donors in Ziguinchor. Health Sciences and Disease, 22.</mixed-citation></ref><ref id="scirp.119634-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Diop, S., Ndiaye, M., Seck, M., Chevalier, B., Jambou, R. and Sarr, A. (2009) Prevention of Transfusion Transmitted Malaria in Endemic Area. Transfusion Clinique et Biologique, 16, 454-459. https://doi.org/10.1016/j.tracli.2009.02.004</mixed-citation></ref><ref id="scirp.119634-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Apata, I.W., Averhoff, F., Pitman, J., Bjork, A., Yu, J., Amin, N.A., et al. (2014) Progress toward Prevention of Transfusion-Transmitted Hepatitis B and Hepatitis C Infection—Sub-Saharan Africa, 2000-2011. Morbidity and Mortality Weekly Report, 63, 613-619.</mixed-citation></ref><ref id="scirp.119634-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Diop, M., Diouf, A., Seck, S.M., Lo, G., Ka, D., Massaly, A., et al. (2017) Prevalence of Hepatitis B Virus Surface Antigen and Associated Factors in Senegalese Military Personnel Deployed to Darfur. The Pan African Medical Journal, 26, Article No. 154.</mixed-citation></ref><ref id="scirp.119634-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Gadji, M., Guéye, Y.B., Ba, A., Senghor, A.B., Seck, R., Faye, B.F., et al. (2017) Evaluation of the Chemiluminescence Technique for the Testing of HBV, HCV and HIV Viral Agents in Blood Donations at the National Blood Transfusion Centre in Dakar. Trans-Fusion Clinic and Biologic, 24, 356. https://doi.org/10.1016/j.tracli.2017.06.238</mixed-citation></ref><ref id="scirp.119634-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">W.H.O. (2007) WHO Global Strategic Plan, 2008-2015: Universal Access to Safe Blood Transfusion. WHO, Geneva.</mixed-citation></ref><ref id="scirp.119634-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2012) Blood Donor Selection: Guidelines on Assessing Donor Suitability for Blood Donation. World Health Organization, Geneva.</mixed-citation></ref></ref-list></back></article>